Intended for EU healthcare professionals only. The information on this website is not country-specific. This is an international disease awareness campaign.
Back
Infographic

What are predictors for achieving MDA at 6 months in early PsA patients?

Based on a study by Zabotti A et al. presented at EULAR 2023.

Download

Published on

10 Nov 2023
Download

Get similar content directly to your inbox.

Never miss an insight. Register your interest and we'll let you know when new articles are published on this topic

PsA patients in the SIRENA registry were classified according to ASAS criteria and were DMARD-naïve for SpA at baseline. Of 203 PsA patients, 100 were prescribed csDMARDs, 50 bDMARDs, and 27 other systemic treatments, mostly NSAIDs. Treatment could be switched during the observation period. The 6-month predictors of MDA presented here were identified through univariate analyses. In multivariate analyses, no factors were identified as significant predictors of MDA at 6 months.1

ASAS: Assessment of SpondyloArthritis international Society; BSA: body surface area; DAPSA: Disease Activity in Psoriatic Arthritis; (b/cs)DMARD: (biologic/conventional synthetic) disease-modifying anti-rheumatic drug; HAQ-DI: Health Assessment Questionnaire-Disability Index; MDA: Minimal Disease Activity; NSAIDs: non-steroidal anti-inflammatory drugs; PsA: psoriatic arthritis; SpA: spondyloarthritis.

1. Zabotti A et al. Ann Rheum Dis. 2023;82(Suppl 1):348. Abstract POS0233. 2. Mease PJ et al. Arthritis Rheumatol. 2022;74(Suppl 9). Abstract 1493.